Dr John Beadle, MBBCh, MBA, brings a wealth of experience and knowledge in the development of clinical stage biotech companies. He was previously founding Chief Executive Officer of PsiOxus Therapeutics, founder and Chief Medical Officer of PowderMed, Entrepreneur-in-Residence at Imperial innovations, Site Head at Pfizer and Vice President of Global Medical Operations at GlaxoSmithKline. To date, he has raised in excess of $150M and realised transaction values in excess of $300M within the biotech industry.
Founder and CEO
Davidson is an entrepreneurial bioengineer with a successful track record of managing and financing disruptive early stage technology projects. He has an interdisciplinary background in the physical and life sciences with a BEng in Biomedical Materials and a PhD in Bioengineering from Queen Mary University of London. He was a recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship during which he had a year of business training at the endowed Hunter Centre for Entrepreneurship of Strathclyde Business School. He has raised over $3.5M in non-dilutive and risk capital. He has secured a number of alliances and progressed BioMoti’s innovative Oncojan cancer therapeutics platform towards clinical development.
Founder and NED
Jo is Professor of Pathology, Deputy Vice Principal Health and Director of the Blizard Institute at Queen Mary University of London. She is also Consultant Histopathologist at Barts Health NHS Trust and National Specialty Advisor for Pathology at NHS England. She was previously the President of The Royal College of Pathologists. Jo has an international reputation in the study of diseases with over 125 publications including high impact journals such as Science and Nature. She is an experienced business leader (MA in Leadership) with a track record of running a large NHS Trust Division (£89 million budget per annum), delivering and commissioning a £40 million building, and 2 major IT system implementations.